Us Bancorp \De\ Adaptimmune Therapeutics PLC Transaction History

Us Bancorp \De\

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 09, 2023	BUY	$0.9 - $1.51 $952 - $1,597	1,058 New	1,058 $0
Q3 2022 Oct 27, 2022	BUY	$1.06 - $2.41 $15,835 - $36,002	14,939 Added 1345.86%	16,049 $18,000
Q2 2022 Aug 01, 2022	SELL	$1.33 - $2.28 $12,458 - $21,356	-9,367 Reduced 89.41%	1,110 $2,000
Q1 2022 May 11, 2022	BUY	$1.73 - $4.06 $10,428 - $24,473	6,028 Added 135.49%	10,477 $22,000
Q4 2021 Feb 11, 2022	SELL	$3.5 - $5.68 $4,480 - $7,270	-1,280 Reduced 22.34%	4,449 $17,000
Q3 2021 Nov 10, 2021	BUY	$3.44 - $6.37 $15,789 - $29,238	4,590 Added 402.99%	5,729 $29,000
Q2 2021 Aug 05, 2021	SELL	$3.86 - $5.78 $725 - $1,086	-188 Reduced 14.17%	1,139 $5,000
Q1 2021 Apr 28, 2021	SELL	$4.9 - $6.83 $534 - $744	-109 Reduced 7.59%	1,327 $7,000
Q4 2020 Feb 04, 2021	SELL	$4.0 - $9.2 $1,884 - $4,333	-471 Reduced 24.7%	1,436 $7,000
Q3 2020 Nov 10, 2020	BUY	$7.66 - $10.78 $4,205 - $5,918	549 Added 40.43%	1,907 $15,000
Q2 2020 Aug 07, 2020	SELL	$2.58 - $12.1 $1,586 - $7,441	-615 Reduced 31.17%	1,358 $14,000
Q1 2020 May 13, 2020	BUY	$1.2 - $4.52 $2,367 - $8,917	1,973 New	1,973 $5,000

123M

34.2K

16.3K

Ticker ADAP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 163,370,000
Market Cap $73.5M
Description
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...

Get notified when there are updates to the investment portfolio of Us Bancorp \De\, based on Form 13F filings with the SEC.

Stay updated on Us Bancorp \De\ with notifications on news.